研发持续投入，金葡菌疫苗三期临床推进中

| --- | --- | --- | --- | --- | --- | |------------------------------------------|-----------|--------------|-------------|----------------------------------|-------------| | 盈利预测和财务指标 | 2022 | 2023 | 2024E | 2025E | 2026E | | 营业收入(百万元 ) | 547 | 496 | 658 | 825 | 1,067 | | (+/-%) | 12.4% | -9.4% | 32.7% | 25.3% | 29.3% | | 净利润 (百万元) | 27 | 18 | 79 | 112 | 172 | | (+/-%) | -75.4% | -33.9% | 348.0% | 42.0% | 54.4% | | 每股收益（元） | 0.07 | 0.04 | 0.19 | 0.28 | 0.42 | | EBIT Margin | 5.6% | 2.0% | 10.4% | 11.8% | 1 ...